ArticleApplied biochemistry and biotechnology2026
Exosome-derived CDNF Inhibits Astrocyte and T Cell Activation by Regulating HSPA5 and Promotes Repair and Regeneration after Peripheral Nerve Injury.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePeripheral nerve injury (PNI) often triggers a detrimental neuroinflammatory response involving astrocytes and T-cells, hindering functional recovery. This study aimed to investigate the mechanism by which Cerebral Dopamine Neurotrophic Factor (CDNF) modulates astrocyte and T-cell activation and to evaluate its therapeutic potential for promoting nerve regeneration.
methodsExosomes (Exo) were engineered to carry CDNF by isolating them from bone marrow mesenchymal stem cells (BMSCs) overexpressing CDNF. The effects of CDNF on the activation of cultured astrocytes and CD8+ T-cells were assessed in vitro by measuring cytokine release, cell proliferation, and activation markers using ELISA, EdU assays, flow cytometry, and Western blotting. Co-immunoprecipitation was employed to investigate the interaction between CDNF and Heat Shock Protein A5 (HSPA5). The therapeutic efficacy of exosome-delivered CDNF (Exo-CDNF) was evaluated in vivo using a rat model of chronic constriction injury (CCI), a model for PNI-induced neuropathic pain.
resultsCDNF suppressed the activation of astrocytes and CD8+ T-cells, as evidenced by reduced production of pro-inflammatory cytokines (TNF-α, IL-1β), decreased cell proliferation, and attenuated NF-κB pathway activation. Exo-CDNF was effectively internalized by astrocytes and T-cells, exerting similar inhibitory effects. Mechanistically, we discovered a direct interaction between CDNF and HSPA5. Overexpression of HSPA5 counteracted the immunosuppressive effects of CDNF. In vivo, systemic administration of Exo-CDNF alleviated neuropathic pain behaviors, reduced spinal cord apoptosis and neuroinflammation, and improved histological outcomes in CCI rats.
conclusionOur findings demonstrate that Exo-mediated delivery of CDNF effectively suppresses astrocyte and T-cell activation by regulating HSPA5. This study reveals a novel immunomodulatory role for the CDNF-HSPA5 axis and highlights Exo-CDNF as a promising therapeutic strategy for promoting repair and regeneration following peripheral nerve injury.
Indexed as
Identifiers
41504843What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.